CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank75
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-19.39M
↑ 66% vs avg
Percentile
P75
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-56.30M
Historical baseline
PeriodValueYoY Change
TTM$-19.39M-172.5%
2024$26.76M+721.1%
2023$-4.31M+95.6%
2022$-98.89M+12.7%
2021$-113.34M-45.4%
2020$-77.97M+22.1%
2019$-100.06M-31.7%
2018$-75.99M-81.1%
2017$-41.97M+27.5%
2016$-57.85M-